Scandion Oncology Valuation

Is SCOL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SCOL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate SCOL's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate SCOL's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SCOL?

Key metric: As SCOL is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for SCOL. This is calculated by dividing SCOL's market cap by their current book value.
What is SCOL's PB Ratio?
PB Ratio	0.5x
Book	DKK 23.70m
Market Cap	DKK 11.47m

SCOL key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	n/a
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does SCOL's PB Ratio compare to its peers?

The above table shows the PB ratio for SCOL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	57.3x
ACTI Active Biotech	224.9x	62.1%	SEK 344.4m
KAN Kancera	1.6x	47.8%	SEK 130.9m
LIDDS LIDDS	2.4x	n/a	SEK 14.4m
DIABIO Diagonal Bio	0.5x	n/a	SEK 13.4m
SCOL Scandion Oncology	0.5x	69.7%	SEK 17.9m

Price-To-Book vs Peers: SCOL is good value based on its Price-To-Book Ratio (0.5x) compared to the peer average (57.3x).

Price to Book Ratio vs Industry

How does SCOL's PB Ratio compare vs other companies in the SE Biotechs Industry?

8 Companies	Price / Book	Estimated Growth	Market Cap
Industry Avg.	2.4x	44.9%
SCOL Scandion Oncology	0.5x	69.7%	US$1.62m
COMBI CombiGene	0.6x	n/a	US$4.45m
CYXO Cyxone	0.5x	n/a	US$1.43m

8 Companies		Estimated Growth	Market Cap
Industry Avg.	2.4x	44.9%
SCOL Scandion Oncology	0.5x	69.7%	US$1.62m

No more companies

Price-To-Book vs Industry: SCOL is good value based on its Price-To-Book Ratio (0.5x) compared to the Swedish Biotechs industry average (2.4x).

Price to Book Ratio vs Fair Ratio

What is SCOL's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SCOL PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	0.5x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate SCOL's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

PMD Device Solutions

SEK 36.3m

A digital medical device company, develops and sells respiratory monitoring solutions in Ireland.

PMDS

SEK 1.40

-6.0%

n/a

Swedish Orphan Biovitrum

SEK 99.5b

An integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia.

SOBI

SEK 289.80

-10.9%

20.1%

Corline Biomedical

SEK 148.7m

Develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications.

CLBIO

SEK 6.92

4.8%

-40.3%